Christin Wesström

Christin Wesström is a declared insider of Swedish Orphan Biovitrum AB (publ) (chief executive), with filings sourced from Finansinspektionen. In total, 21 filings cover trades dated from 8 June 2022 to 30 July 2026.

On the open market, the record shows 6 purchases worth €3.4M and 8 sales worth €6.6M. The net balance comes to €3.2M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 5 share grants. So far in 2026, the count stands at 2 purchases and 3 sales.

Half of the purchases are above €560k and half below. Clusters matter here: 4 out of 5 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 30 July 2026, the filings show an open-market sale worth €1.5M in Swedish Orphan Biovitrum AB (publ). The most recent open-market purchase was published on 30 July 2026, 86 days ago. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 2 days. For comparison, MAR article 19 gives managers three business days to notify a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.